Q-omics provides the consensus-scored KANSL1L profile across patient tissues and cancer cell-line models. KANSL1L expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KANSL1L is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, KANSL1L RNA expression shows 21,696 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, KICH, and THYM as cancer lineages where KANSL1L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KANSL1L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KANSL1L survival associations across molecular data types. KANSL1L RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KANSL1L RNA expression–survival associations across cancer types. High KANSL1L expression shows unfavorable associations in ACC and LGG, but favorable associations in KIRC, LAML, UCS and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KANSL1L RNA expression.
This table summarizes KANSL1L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in KICH for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for KANSL1L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KANSL1L shows lower tumor expression in KICH, LUSC, UCEC, THCA and BRCA and higher tumor expression in KIRP. The KICH box plot shows higher KANSL1L RNA expression in normal versus tumor tissue (log2 FC = −1.881, t-test p < 0.001).
This table shows molecular features associated with KANSL1L in patient tissues and cancer cell lines. In patient samples, KANSL1L shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, KANSL1L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Leukemia.
